Lipids, Inflammation, and CV Risk in RA: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Lipids, Inflammation, and CV Risk in RA (NCT02714881), a registered phase not stated study. The primary outcome is Coronary Flow Reserve.

2. Clinical Question

The broader objective was to examine relationships among inflammation, lipids, and cardiovascular risk in rheumatoid arthritis. A further hypothesis was that lipid levels might have a weaker relationship with cardiovascular risk than in the general population. These are research questions, not findings: the registry record does not report results establishing either relationship.

3. Trial Design

This completed study was registered as “Lipids, Inflammation, and CV Risk in RA,” with the official title “Lipids, Inflammation, and Cardiovascular Risk in Rheumatoid Arthritis.” Brigham and Women’s Hospital is listed as the sponsor. The registry gives a start date of 2016-10-17 and a primary completion date of 2020-12-14.

The design described in the record is an observational before-and-after assessment around usual-care initiation of a tumor necrosis factor inhibitor. Participants were to have measurements of inflammatory biomarkers, lipids and advanced lipoproteins, and coronary flow reserve before and after TNFi. The record does not describe random assignment, and allocation is not stated. It explicitly notes that this is not a randomized comparison and that arms are not a like-for-like control comparison.

The registry reports enrollment of 74 and explains that one enrolled person changed their mind during the baseline study visit; the primary-outcome population description says 73 were studied. This distinction matters: enrollment is not automatically the same as having measurements available for analysis. The record does not state how many participants contributed data at each measurement time or to any particular analysis.

Certolizumab is listed as a drug intervention, while the arm description refers more generally to people about to initiate a TNFi as part of usual care. The record does not provide enough detail to infer that the listed drug was used by every participant or to identify a separate untreated comparison group. Although the study status is completed, completion alone does not supply evidence about the size or direction of any change.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Analysis population for the primary outcome, as defined in the registry: n=1 subject enrolled, however changed their mind during the baseline study visit. Thus, enrolled n=74 and studied is n=73.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Coronary Flow Reserve, measured over 24 weeks.

The primary endpoint is coronary flow reserve (CFR), recorded as a continuous measure with a mean and standard deviation. Its unit is a ratio. The registry defines CFR as myocardial blood flow under stress divided by myocardial blood flow at rest, with the assessment scheduled at 24 weeks.

The stated rationale is that CFR can serve as a cardiac imaging biomarker of coronary vasomotor function and as a surrogate cardiovascular outcome in rheumatoid arthritis. In general, a continuous measure can describe a range of values rather than placing each person into a simple event/no-event category. A mean gives a measure of the group’s central level, while a standard deviation describes spread among observed values. Neither statistic by itself indicates how precisely a treatment-related change has been estimated.

The study’s central hypothesis links reduced inflammation with reduced cardiovascular risk as measured by CFR. That hypothesis does not make a change in CFR equivalent to a demonstrated change in clinical cardiovascular events. The registry record does not report a mean CFR, standard deviation, change from baseline, confidence interval, or statistical test result. It therefore does not establish the observed direction, magnitude, or precision of any endpoint change.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry describes a continuous primary measure, CFR, represented by a mean and standard deviation. In general, a mean is the arithmetic average of observed values and provides a compact description of their central location. A standard deviation describes how dispersed individual values are around that mean. These summaries answer different questions: the mean describes a typical level, while the standard deviation describes variability among measurements. Neither alone provides the uncertainty around an estimated mean or mean change.

What would a before-and-after analysis describe?

In general, a paired analysis uses measurements from the same participants at two times and focuses on each participant’s change. This takes account of the fact that two measurements from one person are related rather than independent. For this study, the arm description says CFR was measured before and after TNFi, with the primary timeframe listed as 24 weeks. However, the registry record does not report a paired change estimate, its standard error, or the number of complete pairs. It is therefore not possible to assess which analysis was used or what it found.

A different approach might summarize values at each time separately or model repeated measurements, but the choice and details of any statistical model are not reported in the registry record. The statistical plan, including any adjustment variables or assumptions, is also not reported. These are general examples of analytical choices, not claims about the methods used in this study.

How should uncertainty be understood?

In general, a confidence interval gives a range of values compatible with the data under the assumptions of the analysis. Its width communicates precision: a narrower interval indicates greater precision than a wider interval. A point estimate without an interval can conceal substantial uncertainty, especially when the number of usable observations is limited. Here, no confidence interval or other uncertainty estimate for CFR is reported in the registry record.

In general, a p-value evaluates how compatible the observed data are with a specified statistical null model; it does not give the probability that a hypothesis is true, nor does it quantify clinical importance. A p-value is most useful when read alongside an effect estimate and its uncertainty. The registry reports no p-value or analysis for the primary outcome, so statistical significance cannot be assessed from the record.

What do the planning assumptions mean?

The registry’s sample-size assumptions describe a planning illustration based on an observed effect, not the study’s own design justification. The stated conventions are a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation; the effect to detect is described as a stated fraction of the observed effect. For time-to-event calculations, the convention is a total number of events; for other calculations, it is participants per arm.

These assumptions do not establish that the study had two randomized arms. The study description does not report a like-for-like control comparison, and the registry does not report an allocation method. Planning illustrations are hypothetical calculations under their stated assumptions; they are not observed power and do not show that the study was adequately powered. Numerical planning results and a sample-size justification are not reported in the registry record.

What is not documented?

The record lists one outcome measure and zero analyses. It does not report the statistical analysis plan, the specific test or model, adjustments, diagnostics, or the approach to missing data. It also does not report a primary-outcome estimate, confidence interval, or p-value. In general, knowing these details helps readers judge whether the analysis follows the design, whether assumptions are plausible, and how much uncertainty remains. Without them, interpretation must remain descriptive and limited to the registered study question and measurement plan.

10. Confidence Intervals for Each Arm

No two-arm comparison is shown for this trial, but each arm's mean can be given with a t-based 95% confidence interval computed from the posted mean, spread and number of participants.

R code and output

arm <- c("Tumor Necrosis Factor Inhibitor")
n   <- c(73)
m   <- c(2.65)
sp  <- c(0.56)
sd  <- sp      # posted standard deviations
for (i in seq_along(n)) {
  se <- sd[i] / sqrt(n[i]); h <- qt(0.975, n[i] - 1) * se
  cat(sprintf("CARM|%s|%d|%.3f|%.3f|%.3f|%.3f\n", arm[i], n[i], m[i], sd[i], m[i] - h, m[i] + h))
}

CARM  Tumor Necrosis Factor Inhibitor  73  2.650  0.560  2.519  2.781

11. Multiplicity, Missing Data and Analysis Populations

The record lists one outcome measure and zero analyses. It identifies CFR as the primary measure, but does not report an analysis plan or describe how multiple outcomes, time points, biomarkers, or hypotheses were handled. A multiplicity procedure is not reported in the registry record. In general, when several statistical questions are tested, the chance of obtaining at least one apparently notable result can increase; prespecifying a primary question and an approach to multiple testing can help readers interpret findings. No correction or testing hierarchy should be assumed.

Missing-data methods are not reported in the registry record. The primary-outcome population description states that one enrolled person changed their mind during the baseline study visit and that 73 were studied. That does not establish how many had measurements at both time points, whether any later observations were missing, or how missing values were handled. In general, excluding people with incomplete data can affect the analysis if the reasons for missingness are related to measurements or outcomes.

The record does not define an analysis population beyond its enrollment and studied counts, and does not state whether all available observations or complete pairs were used. The statistical plan and any interim analyses are not reported in the registry record. These omissions prevent assessment of whether the reported population, missing-data handling, and statistical testing were prespecified. Because no analysis results are listed, there is also no reported estimate to evaluate for multiplicity or missing-data sensitivity.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: fracture (1.4%), upper respiratory infection (1.4%).

The registry lists serious adverse events for the Tumor Necrosis Factor Inhibitor group, with 74 at risk and 2 affected; deaths are listed as 0. It separately lists other adverse events, with 74 at risk and 23 affected. These are the registry’s group-level counts and should be read as reported, not recalculated or treated as outcome-efficacy measures.

The serious-event terms listed among the most common are fracture and upper respiratory infection, each reported as 1.4%. These percentages are registry entries; the record does not provide further detail in the registry record about event timing, severity beyond the serious-event classification, recurrence, or attribution to treatment. A listed event during a study does not by itself establish that the intervention caused it.

In general, adverse-event counts describe events recorded under a study’s collection and reporting procedures. They do not alone establish comparative risk, particularly when the record does not describe a like-for-like control group. The registry does not report an adjusted safety comparison or analysis. The listed figures should therefore be interpreted as descriptive safety reporting, not as evidence that TNFi did or did not cause any event.

13. What the Result Does, and Does Not, Mean

The record documents an investigation of inflammation, lipids, and cardiovascular risk in rheumatoid arthritis, with CFR selected as the primary measure. It describes measurement before and after usual-care TNFi initiation and identifies 24 weeks as the primary timeframe. The record also gives enrollment and studied-population information. These details clarify the research question and the intended measurement context.

They do not establish what happened to CFR. The registry record reports no primary-outcome analysis, mean, change estimate, confidence interval, or p-value. As a result, the posted information does not show whether CFR increased, decreased, or remained similar, and it does not show how precisely any change was measured. The absence of an analyzed result should not be interpreted as evidence of no change.

The stated aim of examining relationships among inflammation, lipids, and cardiovascular risk is also not answered by the available results. No association estimates are reported. The central hypothesis about inflammation and the additional hypothesis about lipid levels remain hypotheses in this record rather than confirmed or refuted findings.

Even if a before-and-after difference were reported, general statistical interpretation would need to distinguish an observed time-related change from a treatment effect. The study is not described as randomized and does not identify a like-for-like control group. Other changes over time or accompanying care could contribute to a before-and-after pattern. The record also does not describe the statistical model, missing-data procedures, or uncertainty estimates needed to judge the robustness and precision of an analysis.

The safety counts provide descriptive information about adverse events recorded in the group, but they do not supply a randomized comparison or establish causation. Overall, the registry entry supports a description of the study question, endpoint, and broad design. It does not support a conclusion about treatment benefit, lack of benefit, or causal safety effects.

14. Why This Trial Matters Statistically

This study is statistically notable for pairing a mechanistic cardiovascular measure with questions about inflammation and lipids in rheumatoid arthritis. CFR is described as a ratio of myocardial blood flow under stress to flow at rest, and the registry identifies it as a measure of coronary vasomotor function and a surrogate cardiovascular outcome. The choice makes the measurement question more specific than a general assessment of cardiovascular risk, while also requiring care not to equate a biomarker with a clinical event outcome.

The before-and-after structure raises a central design issue: repeated measurements in the same participants can be informative about change, but without a like-for-like control group they do not by themselves isolate a treatment effect. The registry explicitly notes that the comparison is not randomized and that arms are not a like-for-like control comparison. This matters when interpreting any apparent change, even though no outcome analysis is reported.

The record also illustrates why population definitions and analysis details matter. It distinguishes 74 enrolled from 73 studied after one participant changed their mind during the baseline visit, but does not report the number of complete paired measurements. Without an analysis population, missing-data strategy, and uncertainty estimates, readers cannot judge the precision or potential sensitivity of a result.

Finally, registration of a primary measure and study hypotheses is not the same as posting analyzed results. The record identifies an important research question, but lists no analyses. Statistically, the main lesson is to separate the rationale and measurement plan from evidence about effect size, uncertainty, and causal interpretation.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The outcome reporting is the most direct limitation for interpretation: the registry identifies CFR as the primary measure but reports no analysis or result. There is no estimate of mean CFR or change, and no uncertainty measure or statistical test. The direction, magnitude, and precision of the primary outcome therefore remain unknown in this record.

The design is described as before-and-after measurement around TNFi initiation as usual care, not as a randomized comparison. The registry says allocation is not stated and that the arms are not a like-for-like control comparison. A time-related difference, if reported elsewhere, could not automatically be attributed to TNFi on the basis of this design description alone.

The population description says that one enrolled person changed their mind during the baseline study visit and that 73 were studied. It does not identify how many had complete measurements at both time points or how missing observations were handled. The analysis population, missing-data methods, and statistical model are not reported in the registry record.

The record lists certolizumab as an intervention but describes participants more broadly as starting a TNFi under usual care. It does not specify whether all participants received the listed drug. Details about treatment exposure and variation in care are therefore limited in the available description.

The registry also does not report a statistical analysis plan, multiplicity approach, interim analyses, or sample-size justification. Its planning assumptions are described as an illustration rather than the trial’s design justification. Together, these gaps limit assessment of prespecification, precision, and the scope of any conclusions, beyond the absence of posted outcome analyses.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Lipids, Inflammation, and CV Risk in RA — NCT02714881.
• Registry record last updated 2026-01-21; status last verified 2025-12.
• Results first posted 2026-01-21.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

NCT02714881 is a completed study sponsored by Brigham and Women’s Hospital, with a start date of 2016-10-17 and a primary completion date of 2020-12-14. It examined inflammation, lipids, and cardiovascular risk in rheumatoid arthritis among people about to initiate a TNFi as part of usual care.

The primary measure was CFR, a continuous ratio assessed at 24 weeks. The record reports 74 enrolled and states that 73 were studied after one person changed their mind during the baseline visit. It describes measurements before and after TNFi, but not a randomized or like-for-like control comparison.

The registry lists one outcome measure and no analyses. It does not report a primary-outcome estimate, statistical test, confidence interval, analysis plan, or missing-data method. The posted record therefore establishes the study question and broad measurement approach, but not an analyzed result.